Abstract
OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.
METHODS: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).
RESULTS: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.
CONCLUSION: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Psychiatry investigation |
Vol/bind | 5 |
Udgave nummer | 2 |
Sider (fra-til) | 102-5 |
Antal sider | 4 |
ISSN | 1738-3684 |
DOI | |
Status | Udgivet - jun. 2008 |
Udgivet eksternt | Ja |